[HTML][HTML] Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial

R Ella, KM Vadrevu, H Jogdand, S Prasad… - The Lancet Infectious …, 2021 - thelancet.com
Background To mitigate the effects of COVID-19, a vaccine is urgently needed. BBV152 is a
whole-virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist …

[HTML][HTML] Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3 …

…, V Sarangi, B Ganneru, S Prasad… - The Lancet Infectious …, 2021 - thelancet.com
Background BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine (3 μg or 6 μg)
formulated with a toll-like receptor 7/8 agonist molecule (IMDG) adsorbed to alum (Algel). We …

Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial

…, G Sapkal, N Gupta, P Abraham, S Panda, S Prasad… - The Lancet, 2021 - thelancet.com
Background We report the clinical efficacy against COVID-19 infection of BBV152, a whole
virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist …

Pendred syndrome, DFNB4, and PDS/SLC26A4 identification of eight novel mutations and possible genotype–phenotype correlations

C Campbell, RA Cucci, S Prasad, GE Green… - Human …, 2001 - Wiley Online Library
Mutations in PDS (SLC26A4) cause both Pendred syndrome and DFNB4, two autosomal
recessive disorders that share hearing loss as a common feature. The hearing loss is …

Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial

…, G Curlin, K Mohan, G Harshavardhan, S Prasad… - The Lancet, 2014 - thelancet.com
Background Rotavirus is the most common cause of severe dehydrating gastroenteritis in
developing countries. Safe, effective, and affordable rotavirus vaccines are needed in these …

Mutations in COL11A2 cause non-syndromic hearing loss (DFNA13)

WT McGuirt, SD Prasad, AJ Griffith, HPM Kunst… - Nature …, 1999 - nature.com
We report that mutation of COL11A2 causes deafness previously mapped to the DFNA13
locus on chromosome 6p. We found two families (one American and one Dutch) with …

Mutations in the transcriptional activator EYA4 cause late-onset deafness at the DFNA10 locus

…, N Chen, K Verhoeven, S Prasad… - Human molecular …, 2001 - academic.oup.com
We identified Eyes absent 4 (EYA4), a member of the vertebrate Eya family of transcriptional
activators, as the causative gene of postlingual, progressive, autosomal dominant hearing …

[HTML][HTML] Calcific aortic valve disease: molecular mechanisms and therapeutic approaches

DA Lerman, S Prasad, N Alotti - European Cardiology Review, 2015 - ncbi.nlm.nih.gov
Calcification occurs in atherosclerotic vascular lesions and in the aortic valve. Calcific aortic
valve disease (CAVD) is a slow, progressive disorder that ranges from mild valve thickening …

[HTML][HTML] Phase III Pivotal comparative clinical trial of intranasal (iNCOVACC) and intramuscular COVID 19 vaccine (Covaxin®)

…, AP Singh, S Bawankule, R Ella, S Prasad… - npj Vaccines, 2023 - nature.com
One of the most preferable characteristics for a COVID-19 vaccine candidate is the ability to
reduce transmission and infection of SARS-CoV-2, in addition to disease prevention. Unlike …

Genotype–phenotype correlations for SLC26A4-related deafness

H Azaiez, T Yang, S Prasad, JL Sorensen… - Human genetics, 2007 - Springer
Pendred syndrome (PS) and non-syndromic enlarged vestibular aqueduct (EVA) are two
recessive disorders characterized by the association of sensorineural hearing loss (SNHL) with …